About The Study:

Chikungunya is a virus that can be spread through mosquito bites similar to other mosquito-spread illnesses like Zika, malaria, dengue, and West Nile Virus. It is most prevalent in Africa and Asia, but cases can also be found in the United States. Symptoms can include fever, muscle and joint pain, headaches, and rashes. In adults 65 years or older, symptoms can be more severe and even disabling for several months or years.

Currently, there is no vaccine to protect against the Chikungunya virus. As temperatures are on the rise across the globe, it is more important to protect our community from mosquito-borne diseases. 

RCR is conducting a study to test the effectiveness of a phase 3 vaccine to prevent Chikungunya in people who are 65 or older. The study will be 7 months long and consists of  5 office visits and 2 phone call appointments. 

Study-related care is available to participants in the trial at no cost and health insurance is not required nor needed. Compensation for time and travel is available up to $900, for those who qualify.

Qualifications

  • Generally healthy
  • Over the age of 65 years old
  • BMI under 35 kg/m2
  • *Please note, that other conditions may apply